Cell MedX Corp (OTCMKTS:CMXC) Expanding The Scope


Cell MedX Corp (OTCMKTS:CMXC) discovery Phase study done a couple of years ago exposed that its eBalance Technology amplified insulin sensitivity and delimited glycolytic procedures leading in enhanced carriage and use of glucose through a single treatment. With the diabetes instruments projected to surpass $35 billion by 2024, a permitted item that enhances insulin sensitivity has the chance to become a blockbuster therapeutic device.

The details

Since then, further examinations led the firm to spread its focus to comprise ailments like high blood pressure as well as Parkinson’s, where Cell MedX deliberates micro current technology could exhibit to be useful. GBI Research forestalls Parkinson’s to become a market surpassing $3 billion in next 4 years, while Technavio predicts hypertension drugs to register sales surpassing $32 billion by 2020. These are outstanding additional end markets for the breakthrough technology.

Cell MedX’s short-term goal is to get go-ahead for the eBalance technology to resolve general wellness and treat pain. It proposes to preliminary set up pain management solutions by means of qualified supervisory practices, with premium therapies for related ailments to be given by clinicians. Later, it would be launched on market and device will be issued to cure a variety of other sicknesses including Parkinson’s and diabetes on a modified basis, retaining suitable supervisory events, while potentially relating with research institutions to further progress areas of investigation into diverse areas where the know-how has established potential for future application.

Cell MedX’s eBalance Pro is grounded on microcurrent technology. Applying cutting-edge software, it recognizes certain occurrences for microcurrent app through the submission of a bio-feedback algorithm that records and provides customized frequencies to present optimal outcomes which target specific, and in most circumstances, painful conditions.

Upon the conclusion of the imminent studies, the eBalance Pro will be listed as the sole microcurrent therapy for treating specific medical ailments on a personalized basis.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.